View Future GrowthPeak Processing 過去の業績過去 基準チェック /06Peak Processingは1.2%の年平均成長率で業績を伸ばしているが、Pharmaceuticals業界はgrowingで5.8%毎年増加している。売上は成長しており、年平均5.9%の割合である。主要情報1.23%収益成長率16.27%EPS成長率Pharmaceuticals 業界の成長31.22%収益成長率5.91%株主資本利益率n/aネット・マージン-73.16%前回の決算情報31 Dec 2025最近の業績更新Reported Earnings • Oct 05Full year 2025 earnings released: AU$0.009 loss per share (vs AU$0.069 loss in FY 2024)Full year 2025 results: AU$0.009 loss per share (improved from AU$0.069 loss in FY 2024). Revenue: AU$15.5m (up 27% from FY 2024). Net loss: AU$4.84m (loss narrowed 81% from FY 2024). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 31Full year 2024 earnings released: AU$0.085 loss per share (vs AU$0.039 loss in FY 2023)Full year 2024 results: AU$0.085 loss per share (further deteriorated from AU$0.039 loss in FY 2023). Revenue: AU$30.4m (up 21% from FY 2023). Net loss: AU$32.1m (loss widened 134% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 58% per year, which means it is performing significantly worse than earnings.Reported Earnings • Sep 01Full year 2023 earnings released: AU$0.039 loss per share (vs AU$0.04 loss in FY 2022)Full year 2023 results: AU$0.039 loss per share. Revenue: AU$25.1m (up 22% from FY 2022). Net loss: AU$13.7m (loss widened 13% from FY 2022).Reported Earnings • Sep 01Full year 2022 earnings released: AU$0.04 loss per share (vs AU$0.061 loss in FY 2021)Full year 2022 results: AU$0.04 loss per share (up from AU$0.061 loss in FY 2021). Revenue: AU$20.5m (up 78% from FY 2021). Net loss: AU$12.1m (loss narrowed 19% from FY 2021). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings.Reported Earnings • Sep 01Full year 2021 earnings released: AU$0.06 loss per share (vs AU$0.064 loss in FY 2020)The company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2021 results: Revenue: AU$11.5m (up 128% from FY 2020). Net loss: AU$15.0m (loss widened 1.9% from FY 2020).Reported Earnings • Mar 02First half 2021 earnings released: AU$0.035 loss per share (vs AU$0.037 loss in 1H 2020)The company reported a solid first half result with improved revenues and control over costs, although losses were not reduced. First half 2021 results: Revenue: AU$5.10m (up 175% from 1H 2020). Net loss: AU$8.27m (flat on 1H 2020).すべての更新を表示Recent updatesRecent Insider Transactions • Mar 26Independent Non-Executive Chairman recently bought AU$58k worth of stockOn the 23rd of March, Manik Pujara bought around 3m shares on-market at roughly AU$0.017 per share. This transaction amounted to 61% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Manik's only on-market trade for the last 12 months.お知らせ • Feb 02Peak Processing Limited has completed a Follow-on Equity Offering in the amount of AUD 2.72 million.Peak Processing Limited has completed a Follow-on Equity Offering in the amount of AUD 2.72 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 150,000,000 Price\Range: AUD 0.017 Discount Per Security: AUD 0.00102 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 10,000,000 Price\Range: AUD 0.017 Discount Per Security: AUD 0.00102 Transaction Features: Subsequent Direct Listing分析記事 • Jan 27Many Still Looking Away From Peak Processing Limited (ASX:PKP)Peak Processing Limited's ( ASX:PKP ) price-to-sales (or "P/S") ratio of 1.2x might make it look like a strong buy...お知らせ • Jan 20Peak Processing Limited Announces Cessation of Employment of Brian Mbesha as CFO, Effective January 20, 2026Peak Processing Limited announced the immediate cessation of employment of its Canadian-based Chief Financial Officer (CFO), Mr. Brian Mbesha, as part of an internal restructure. This change forms part of a broader and ongoing cost optimisation program focused on strengthening financial discipline and supporting improved operational execution. Financial oversight, reporting, and controls will continue uninterrupted, led by the Company’s existing finance team, with additional interim part-time assistance from an experienced Australian-based external professional services firm accustomed to Australian reporting requirements to fulfil the CFO functions and ensure compliance and continuity during this transition period. Effective immediately on January 20, 2026.Board Change • Jan 01High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Director Matt Adams is the most experienced director on the board, commencing their role in 2025. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Board Change • Nov 01High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Chairman of the Board Vaughan Webber is the most experienced director on the board, commencing their role in 2024. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 05Full year 2025 earnings released: AU$0.009 loss per share (vs AU$0.069 loss in FY 2024)Full year 2025 results: AU$0.009 loss per share (improved from AU$0.069 loss in FY 2024). Revenue: AU$15.5m (up 27% from FY 2024). Net loss: AU$4.84m (loss narrowed 81% from FY 2024). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.Recent Insider Transactions • Oct 03Insider recently sold AU$201k worth of stockOn the 1st of October, Joshua Fegan sold around 11m shares on-market at roughly AU$0.019 per share. This transaction amounted to 19% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of AU$157k more than they bought in the last 12 months.お知らせ • Oct 01Althea Group Holdings Limited, Annual General Meeting, Nov 27, 2025Althea Group Holdings Limited, Annual General Meeting, Nov 27, 2025.お知らせ • Sep 17Althea Group Holdings Limited has completed a Follow-on Equity Offering in the amount of AUD 2.55 million.Althea Group Holdings Limited has completed a Follow-on Equity Offering in the amount of AUD 2.55 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 141,666,667 Price\Range: AUD 0.018 Discount Per Security: AUD 0.00108 Security Features: Attached Options Transaction Features: Subsequent Direct ListingNew Risk • Aug 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$8.0m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$8.0m free cash flow). Negative equity (-AU$574k). Earnings have declined by 5.7% per year over the past 5 years. Shareholders have been substantially diluted in the past year (66% increase in shares outstanding). Minor Risk Market cap is less than US$100m (AU$18.6m market cap, or US$12.2m).New Risk • Jul 31New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 62% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 12% per year over the past 5 years. Shareholders have been substantially diluted in the past year (62% increase in shares outstanding). Minor Risk Market cap is less than US$100m (AU$21.4m market cap, or US$13.8m).分析記事 • Jul 29Little Excitement Around Althea Group Holdings Limited's (ASX:AGH) RevenuesAlthea Group Holdings Limited's ( ASX:AGH ) price-to-sales (or "P/S") ratio of 0.5x might make it look like a strong...分析記事 • Apr 15Althea Group Holdings Limited's (ASX:AGH) Share Price Is Matching Sentiment Around Its RevenuesYou may think that with a price-to-sales (or "P/S") ratio of 0.3x Althea Group Holdings Limited ( ASX:AGH ) is...New Risk • Apr 09New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 30% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 12% per year over the past 5 years. Shareholders have been substantially diluted in the past year (30% increase in shares outstanding). Market cap is less than US$10m (AU$11.0m market cap, or US$6.55m). Minor Risk Share price has been volatile over the past 3 months (15% average weekly change).お知らせ • Feb 19Althea Group Holdings Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.Althea Group Holdings Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 119,000,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Security Name: Common Shares Security Type: Common Stock Securities Offered: 6,000,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Transaction Features: Subsequent Direct Listingお知らせ • Feb 17Althea Group Holdings Limited Appoints Matt Adams as Non-Executive DirectorAlthea Group Holdings Limited announced the appointment of Mr. Matt Adams as a Non-Executive Director, effective 17 February 2025. Mr. Adams is an experienced finance professional with over 25 years of executive-level experience across corporate finance, restructuring, and turnaround sectors. He has held senior leadership positions, including CEO, CFO, and CRO roles for both listed and unlisted entities. He is currently the Managing Director of Dynamic Corporate Investments, a boutique corporate finance firm specialising in restructuring, corporate advisory, and investment. Mr. Adams' extensive background in financial structuring, governance, and risk management will provide valuable strategic insights to AGH as the Company continues to execute its growth initiatives.New Risk • Feb 03New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$14.7m (US$9.05m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 14% per year over the past 5 years. Market cap is less than US$10m (AU$14.7m market cap, or US$9.05m). Minor Risk Shareholders have been diluted in the past year (27% increase in shares outstanding).お知らせ • Jan 31Althea Group Holdings Limited Announces Penelope Dobson Intention to Retire as DirectorAlthea Group Holdings Limited announced that Penelope Dobson has advised her intention to retire as director at the annual general meeting to be held on January 31, 2025.お知らせ • Dec 30Althea Group Holdings Limited, Annual General Meeting, Jan 31, 2025Althea Group Holdings Limited, Annual General Meeting, Jan 31, 2025.New Risk • Dec 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 14% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (28% increase in shares outstanding). Market cap is less than US$100m (AU$17.3m market cap, or US$11.2m).分析記事 • Dec 02Lacklustre Performance Is Driving Althea Group Holdings Limited's (ASX:AGH) 29% Price DropAlthea Group Holdings Limited ( ASX:AGH ) shares have retraced a considerable 29% in the last month, reversing a fair...お知らせ • Oct 30Montu Group UK Ltd completed the acquisition of MyAccess Clinics business in the UK and Ireland of Althea Group Holdings Limited from Althea Group Holdings Limited (ASX:AGH).Montu Group UK Ltd agreed to acquire MyAccess Clinics business in the UK and Ireland of Althea Group Holdings Limited from Althea Group Holdings Limited (ASX:AGH) for AUD 1 million on October 17, 2024. The completion is subject to the following conditions precedent: Transfer of patient information; Execution of an IP Assignment Deed for the assignment of intellectual property rights o Provision and verification of data relating to patient numbers; Completion will occur 5 business days from the date on which the above conditions have been satisfied (or waived by Montu UK); and The Asset Sale Deed otherwise contains terms customary for a transaction of this nature, including in relation to representations and warranties and and is expected to complete in the coming weeks. Montu Group UK Ltd completed the acquisition of MyAccess Clinics business in the UK and Ireland of Althea Group Holdings Limited from Althea Group Holdings Limited (ASX:AGH) on October 29, 2024.分析記事 • Sep 12Althea Group Holdings Limited's (ASX:AGH) Shares Bounce 39% But Its Business Still Trails The IndustryAlthea Group Holdings Limited ( ASX:AGH ) shareholders would be excited to see that the share price has had a great...Reported Earnings • Aug 31Full year 2024 earnings released: AU$0.085 loss per share (vs AU$0.039 loss in FY 2023)Full year 2024 results: AU$0.085 loss per share (further deteriorated from AU$0.039 loss in FY 2023). Revenue: AU$30.4m (up 21% from FY 2023). Net loss: AU$32.1m (loss widened 134% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 58% per year, which means it is performing significantly worse than earnings.お知らせ • Aug 21Althea Group Holdings Limited Announces Board Changes19 August 2024: Althea Group Holdings Limited announced that Mr. Andrew Newbold will step down from his position as Non- Executive Director and Chairman of the Board on 29 August 2024, following a scheduled board meeting. Mr. Vaughan Webber will then assume the role of Chairman, effective immediately on conclusion of this meeting. Mr. Newbold has served as Non-Executive Director and Chairman since September 2018, providing exemplary leadership and guidance during a period of significant growth and transformation for AGH. The Board extend its sincere thanks to Mr. Newbold for his dedication, strategic vision, and commitment to the Company. We wish him all the best in his future endeavours. The Board announced the appointment of Mr. Vaughan Webber as the new Non-Executive Director and Chairman of Althea Group Holdings Ltd, effective immediately upon Mr. Newbold's resignation on 29 August 2024. Mr. Webber is a seasoned company director and finance executive with over 20 years of experience, possessing an in-depth understanding of ASX-listed company operations and governance. His career highlights include: Non-Executive Director, HUB24 Ltd. (2012-2018): Joined during a board restructure to help recapitalise the business, divest non-performing divisions, and support the CEO and management team in developing a robust strategy. Independent Chairman, Wentworth Holdings Ltd. (2009-2013): Oversaw the company's restructuring, the sale of its primary business operations, and the subsequent acquisition by Thorney Opportunities Ltd.お知らせ • Jul 17Althea Group Holdings Limited has completed a Follow-on Equity Offering in the amount of AUD 2.026662 million.Althea Group Holdings Limited has completed a Follow-on Equity Offering in the amount of AUD 2.026662 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 101,333,100 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Transaction Features: Subsequent Direct Listing分析記事 • Jun 08Althea Group Holdings Limited's (ASX:AGH) Prospects Need A Boost To Lift SharesWith a price-to-sales (or "P/S") ratio of 0.3x Althea Group Holdings Limited ( ASX:AGH ) may be sending very bullish...分析記事 • Feb 23Investors Continue Waiting On Sidelines For Althea Group Holdings Limited (ASX:AGH)You may think that with a price-to-sales (or "P/S") ratio of 0.6x Althea Group Holdings Limited ( ASX:AGH ) is...お知らせ • Jan 05Althea Group Holdings Limited, Annual General Meeting, Jan 30, 2024Althea Group Holdings Limited, Annual General Meeting, Jan 30, 2024, at 17:00 AUS Eastern Standard Time. Agenda: To receive the financial statements, Directors's report and auditor's report for the Company for the financial year ended 30 June 2023; to consider the Remuneration Report; to consider the Additional 10% Placement Capacity; to consider the Re-election of Directors; to consider Short Term Incentive - Grant of Performance Rights to Joshua Fegan; to consider the Long Term Incentive - Grant of Performance Rights to Joshua Fegan; and to consider any other business that may be lawfully brought forward.New Risk • Nov 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$7.8m free cash flow). Earnings have declined by 16% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (AU$15.4m market cap, or US$10.1m).Reported Earnings • Sep 01Full year 2023 earnings released: AU$0.039 loss per share (vs AU$0.04 loss in FY 2022)Full year 2023 results: AU$0.039 loss per share. Revenue: AU$25.1m (up 22% from FY 2022). Net loss: AU$13.7m (loss widened 13% from FY 2022).New Risk • Aug 29New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 19% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (AU$16.3m market cap, or US$10.5m).お知らせ • Jul 24Althea Group Holdings Limited Announces Approval for Althea CBD12:THC10 for Reimbursement in IrelandAlthea Group Holdings Limited announced that Ireland's Primary Care Reimbursement Service (`PCRS') has approved Althea CBD12:THC10 for reimbursement in Ireland. In a follow up to the Company's ASX announcement on 20 May 2022, Althea CBD12:THC10 has now been added to the PCRS in the Republic of Ireland, making it free of charge for Irish patients. The Rapid Review Submission for Althea CBD12:THC10 cannabis oil (50 ml), as included in Schedule 1 of the Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) (Amendment) Regulations 2023, has resulted in the assignment of administrative codes to facilitate access to the product in line with the Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) Regulations 2019 (as amended) for the specified therapeutic indications below, with an effective date of 1st August 2023: Spasticity associated with multiple sclerosis resistant to all standard therapies and interventions; Intractable nausea and vomiting associated with chemotherapy, despite the use of standard anti-emetic regimes. The agreed reimbursement price for Althea CBD12:THC10 (50ml) is 327.89, or approximately AUD 540. Multiple sclerosis (MS) is a complex inflammatory disease of the central nervous system (CNS). The onset of the disease is typically between 20 to 40 years of age, and up to 9,000 people live with this chronic condition in Ireland. Approximately 70% to 80% of adults with cancer experience chemotherapy-induced nausea and vomiting (CINV). CINV remains one of the most distressing symptoms associated with cancer therapy and is associated with decreased adherence to chemotherapy.分析記事 • Apr 18Althea Group Holdings Limited (ASX:AGH) Shares Fly 28% But Investors Aren't Buying For GrowthAlthea Group Holdings Limited ( ASX:AGH ) shareholders are no doubt pleased to see that the share price has bounced 28...お知らせ • Feb 03Althea Group Holdings Limited announced that it has received AUD 2.2 million in funding from Obsidian Global Partners, LLCAlthea Group Holdings Limited announced that it has issued unsecured convertible notes for gross proceeds of AUD 2,200,000 on February 3, 2023. The transaction included participation from institutional investor Obsidian Global Partners, LLC. The notes are convertible at a conversion price of $1.5 (AUD 2.1153) into 54,206,846 common shares of the company. The company will pay no interest on the notes. The investor may in its discretion elect to convert one or more convertible securities at the relevant conversion price by providing the company notice, provided that, where an issue of shares would result in the voting power in the company of the investor or any other person exceeding 19.99%.The notes will mature twelve months from the date which is five business days from the date of execution of the relevant agreement. The company also issued 4,800,000 options with an an exercise price equal to 200% of the 5 actual trading days immediately prior to mutual execution of the relevant agreement. The company will pay fee of 6% of the purchase price and AUD 15,000 upfront as legal cost of the transaction.Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Non-Executive Director Jakob Ripshtein was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Nov 07Althea Group Holdings Limited, Annual General Meeting, Nov 29, 2022Althea Group Holdings Limited, Annual General Meeting, Nov 29, 2022, at 17:00 AUS Eastern Standard Time. Agenda: To receive the financial statements, Directors' report and auditor's report for the Company for the financial year ended 30 June 2022; to consider approval for Additional 10% Placement Capacity; to consider re-election of Directors; and to consider other matters.お知らせ • Sep 15Althea Group Holdings Limited Launches Next Generation ProductsAlthea Group Holdings Limited announce its medical cannabis business Althea, has launched two innovative new products to meet patient needs. Commencing with Althea CBD25, Althea has released an exclusive range of soft gelatine capsules (`soft gel capsules') containing Althea's trusted full-spectrum cannabis extract, manufactured to EU-GMP standard. Each capsule of Althea CBD25 contains 25mg of cannabidiol (CBD), and less than 0.25mg of delta-9- tetrahydrocannabinol (THC) per capsule. As a full-spectrum product, Althea CBD25 also contains terpenes, flavonoids and other phytochemicals. Phytochemicals including cannabinoids and terpenes may have synergistic effects, a hypothesis often referred to as the `entourage effect'. Althea's unique range of soft gel capsules are administered orally, offering a gradual onset and extended duration of effect, compared to the rapid onset and shorter duration of effect for products requiring inhalation (dried flower products). In vitro studies have demonstrated effective disintegration of Althea soft gel capsules in less than 10 minutes and there is no significant difference in pharmacokinetic properties expected for patients converting to soft gel capsules from Althea's first generation (or other suppliers') bottled oil products. Why launch Althea CBD25 soft gel capsules?: Solid oral dosage formats are the gold-standard pharmaceutical preparation globally and are widely recognised for maximising patient acceptability and compliance. A consumer preference survey of soft gel capsules versus conventional solid oral dosage forms identified soft gel capsules as the first choice of delivery format. First generation bottled cannabis oils remain a challenge for patients with visual or dexterity impairments, taste intolerances and for patients residing in aged care facilities and hospitals (where medicines are allocated and dispensed). Althea soft gel capsules provide familiarity, convenience and confidence for doctors and patients, delivering precise and standardised dosing of the medicine. The release of soft gel capsules will continue to position Althea as a leader and innovator in the global medical cannabis industry. Schedule 3 Pharmacist only medicine (Australia): Subject to required regulatory approvals, Althea CBD25 soft gel capsules are a candidate to be supplied under the Therapeutic Goods Administration's (TGA) Schedule 3 (Pharmacist Only Medicine) entry for eligible CBD products. This new, non-prescription cannabis channel could allow Australian patients to purchase Althea CBD25 over the counter upon consultation with a pharmacist, without the need for a prescription. What is Althea THC25 dried flower?: Althea THC25 is a new and exclusive ultra-high THC cannabis dried flower product, containing 25% THC and less than 1% of CBD. Greenhouse grown in Canada and produced to meet the stringent standards of a pharmaceutical preparation for inhalation, Althea THC25 also retains a rich terpene and flavonoid profile. Althea THC25 is Althea's highest-concentrated THC dried flower product and will be available across all its `core' international medical cannabis markets (including Germany, UK and Australia). Why launch Althea THC25 dried flower?: Althea has until now focussed primarily on cannabis extracts, however, with a growing number of consumers accessing cannabis dried flower products via the medical framework, Althea THC25 has been introduced to capitalize on this sizeable market opportunity. Market data indicates that dried flower cannabis is the fastest growing product category in Australia and now accounts for 50.6% of the total market (+450% annual growth). The dried flower market is primarily driven by highly concentrated THC products, representing just over half of the total dried flower category. Althea THC25, the first of three new planned dried flower offerings, will be launched globally and supported by Althea's infield sales team, which will focus on educating the 1,400+ registered prescribers in the Althea network.Reported Earnings • Sep 01Full year 2022 earnings released: AU$0.04 loss per share (vs AU$0.061 loss in FY 2021)Full year 2022 results: AU$0.04 loss per share (up from AU$0.061 loss in FY 2021). Revenue: AU$20.5m (up 78% from FY 2021). Net loss: AU$12.1m (loss narrowed 19% from FY 2021). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings.分析記事 • Jul 11We Think Althea Group Holdings (ASX:AGH) Needs To Drive Business Growth CarefullyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...お知らせ • May 20Health Products Regulatory Authority Approves Althea CBD12:THC10 Product of Althea Group Holdings LimitedAlthea Group Holdings Limited announced that the Health Products Regulatory Authority has approved Althea CBD12:THC10 product for prescription and supply in the Republic Ireland. Details: Althea is to enter the Irish medicinal cannabis market following the approval of Althea CBD12:THC10 by Ireland's medicines regulator, HPRA and the Minister for Health. Althea CBD12:THC10 is one of a limited number of medicinal cannabis products available for prescription and supply in the Republic of Ireland. The Company is seeking further product approvals in Ireland. An application will follow for Althea CBD12:THC10 to be added to the Primary Care Reimbursement Service in the Republic of Ireland as part of the Medicinal Cannabis Access Programme (MCAP), making it free of charge for Irish patients prescribed the treatment under the Medicinal Cannabis Access Programme.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Non-Executive Director Jakob Ripshtein was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.分析記事 • Feb 28The Consensus EPS Estimates For Althea Group Holdings Limited (ASX:AGH) Just Fell A LotThe latest analyst coverage could presage a bad day for Althea Group Holdings Limited ( ASX:AGH ), with the covering...分析記事 • Feb 25Is Althea Group Holdings (ASX:AGH) In A Good Position To Invest In Growth?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Board Change • Feb 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Non-Executive Director Jakob Ripshtein was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Breakeven Date Change • Nov 24No longer forecast to breakevenThe analyst covering Althea Group Holdings no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of AU$5.00m in 2023. New forecast suggests the company will make a loss of AU$100.0k in 2023.Reported Earnings • Sep 01Full year 2021 earnings released: AU$0.06 loss per share (vs AU$0.064 loss in FY 2020)The company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2021 results: Revenue: AU$11.5m (up 128% from FY 2020). Net loss: AU$15.0m (loss widened 1.9% from FY 2020).お知らせ • Aug 25Althea Group Holdings Limited announced that it expects to receive AUD 10.644452 million in fundingAlthea Group Holdings Limited announced a private placement of 44,351,885 common shares at an issue price of AUD 0.24 per share for gross proceeds of AUD 10,644,452.40 on August 25, 2021. The transaction will include participation from from existing institutional shareholders, new institutional investors and new sophisticated investors. The transaction is expected to close on August 31, 2021.Price Target Changed • May 06Price target decreased to AU$1.13Down from AU$1.48, the current price target is provided by 1 analyst. New target price is 169% above last closing price of AU$0.42. Stock is up 6.3% over the past year.分析記事 • Mar 13When Will Althea Group Holdings Limited (ASX:AGH) Become Profitable?We feel now is a pretty good time to analyse Althea Group Holdings Limited's ( ASX:AGH ) business as it appears the...Reported Earnings • Mar 02First half 2021 earnings released: AU$0.035 loss per share (vs AU$0.037 loss in 1H 2020)The company reported a solid first half result with improved revenues and control over costs, although losses were not reduced. First half 2021 results: Revenue: AU$5.10m (up 175% from 1H 2020). Net loss: AU$8.27m (flat on 1H 2020).お知らせ • Feb 11Althea Group Holdings Limited Completes the Export of Its First Commercial Shipment of Althea Products to UK-Based Medicinal Cannabis Distributor Grow Pharma GroupAlthea Group Holdings Limited announced that it has completed the export of its first commercial shipment of Althea products to UK-based medicinal cannabis distributor Grow Pharma Group (`Grow Pharma'). A medicinal cannabis supply agreement was signed by the two parties last year, allowing Grow Pharma to distribute Althea products in the UK, in parallel to the Company's own existing sales channel. Following initial success with products supplied to Grow Pharma from its UK inventory, Althea recently expanded its agreement with Grow Pharma to include two further jurisdictions, including the Isle of Man and Guernsey. The Isle of Man and Guernsey are self-governing dependencies of the Crown and medicinal cannabis has been legal in both territories since 2018 and 2019, respectively.お知らせ • Feb 10Althea Group Holdings Limited Completes First Shipment of Products to GermanyAlthea Group Holdings Limited announced that it has completed its first shipment of Althea medicinal cannabis oil products to the Company's local partner in Germany, Nimbus Health GmbH (`Nimbus'). The initial shipment of Althea medicinal cannabis oil products valued at approximately $1,000,000 (EUR 640,000) has arrived at the Nimbus facility and will be distributed through a large network of existing partnering pharmacies. In conjunction with Nimbus, Althea will generate its own sales via new and existing customers and will not rely on third party wholesalers for repeat purchase orders. Exclusive supply & distribution agreement: Althea announced a Memorandum of Understanding in November 2019, followed by a Supply and Distribution Agreement in May 2020. Under the agreement, Althea will receive payment for products supplied to Nimbus, along with 50% of net profit. In addition, Althea will retain ownership of all real-world anonymized patient data collected through its industry-leading medical app, Althea ConciergeTM. To launch the Althea brand in Germany, Nimbus is adopting the same successful market access strategy implemented by the Company in Australia and the UK.分析記事 • Feb 06Can You Imagine How Althea Group Holdings' (ASX:AGH) Shareholders Feel About The 28% Share Price Increase?These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But investors can...お知らせ • Dec 18Althea Group Holdings Limited Announces Availability of CBD Medicines For Over-The-Counter Sale from 2021Althea Group Holdings Limited announced that a major regulatory change has been confirmed in relation to the status of cannabidiol (CBD) in Australia. TGA confirms new Schedule 3 entry for CBD The Therapeutic Goods Administration issued its final decision on proposed amendments to the Poison Standard which, amongst other amendments, sees a new Schedule 3 entry created for cannabidiol. The date of effect of the decision is 1 February 2021, bringing it forward from the date of 1 June 2021 as proposed in the interim decision. The amendment will allow CBD to be supplied for therapeutic use under a new Schedule 3 (Pharmacist Only Medicine) entry. This new, non-prescription cannabis channel would allow Australian patients to purchase CBD products over the counter upon consultation with a pharmacist, without the need for a prescription. Maximum recommended daily dose increased The final decision included a modification to the dose specified in the interim decision, increasing from 60 mg/day, up to 150 mg/day. The decision paves the way for Althea's top selling full-spectrum CBD product, Althea CBD100, to be made available under Schedule 3 (currently sold in Schedule 4 - Prescription Only Medicine). Althea CBD100, along with several other CBD preparations currently in development, would need to be included in the Australian Register of Therapeutic Goods (ARTG) to be made available for sale as Schedule 3 products. The Company maintains robust drug master files for its medications and is confident in its ability to meet the ARTG requirements for Schedule 3 preparations.お知らせ • Dec 16Althea Group Holdings Limited announced that it expects to receive AUD 6 million in fundingAlthea Group Holdings Limited (ASX:AGH) announced a private placement of 13,636,364 common shares at an issue price of AUD 0.44 per share for gross proceeds of AUD 6,000,000 on December 14, 2020. The transaction is expected to close December 21, 2020. The transaction will include participation from to institutional, sophisticated and professional investors.分析記事 • Dec 04What You Need To Know About Althea Group Holdings Limited's (ASX:AGH) Investor CompositionEvery investor in Althea Group Holdings Limited ( ASX:AGH ) should be aware of the most powerful shareholder groups...お知らせ • Jun 22Althea Group Holdings Limited(ASX:AGH) dropped from S&P/ASX Emerging Companies IndexAlthea Group Holdings Limited(ASX:AGH) dropped from S&P/ASX Emerging Companies Index収支内訳Peak Processing の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史ASX:PKP 収益、費用、利益 ( )AUD Millions日付収益収益G+A経費研究開発費31 Dec 2515-1111030 Sep 2513-89030 Jun 2515-510031 Mar 2513-99031 Dec 2428-1924030 Sep 2429-2525030 Jun 2412-2611031 Mar 2419-2316031 Dec 2326-1921030 Sep 2326-1622030 Jun 2325-1424031 Mar 2324-1422031 Dec 2223-1421030 Sep 2222-1320030 Jun 2221-1219031 Mar 2218-1320031 Dec 2116-1420030 Sep 2114-1420030 Jun 2112-1519031 Mar 2110-1517031 Dec 208-1515030 Sep 207-1515030 Jun 205-1514031 Mar 204-1514031 Dec 192-1514030 Sep 192-1211030 Jun 191-99031 Dec 180-44030 Sep 180-33030 Jun 180-110質の高い収益: PKPは現在利益が出ていません。利益率の向上: PKPは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: PKPは利益を出していないが、過去 5 年間で年間1.2%の割合で損失を削減してきた。成長の加速: PKPの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: PKPは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( -17.4% ) と比較することは困難です。株主資本利益率高いROE: PKPの負債は資産を上回っているため、自己資本利益率を計算することは困難です。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/12 07:06終値2026/06/12 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Peak Processing Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関null nullPAC Partners Securities Pty. Ltd.Alexander SmithPAC Partners Securities Pty. Ltd.
Reported Earnings • Oct 05Full year 2025 earnings released: AU$0.009 loss per share (vs AU$0.069 loss in FY 2024)Full year 2025 results: AU$0.009 loss per share (improved from AU$0.069 loss in FY 2024). Revenue: AU$15.5m (up 27% from FY 2024). Net loss: AU$4.84m (loss narrowed 81% from FY 2024). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 31Full year 2024 earnings released: AU$0.085 loss per share (vs AU$0.039 loss in FY 2023)Full year 2024 results: AU$0.085 loss per share (further deteriorated from AU$0.039 loss in FY 2023). Revenue: AU$30.4m (up 21% from FY 2023). Net loss: AU$32.1m (loss widened 134% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 58% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Sep 01Full year 2023 earnings released: AU$0.039 loss per share (vs AU$0.04 loss in FY 2022)Full year 2023 results: AU$0.039 loss per share. Revenue: AU$25.1m (up 22% from FY 2022). Net loss: AU$13.7m (loss widened 13% from FY 2022).
Reported Earnings • Sep 01Full year 2022 earnings released: AU$0.04 loss per share (vs AU$0.061 loss in FY 2021)Full year 2022 results: AU$0.04 loss per share (up from AU$0.061 loss in FY 2021). Revenue: AU$20.5m (up 78% from FY 2021). Net loss: AU$12.1m (loss narrowed 19% from FY 2021). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings.
Reported Earnings • Sep 01Full year 2021 earnings released: AU$0.06 loss per share (vs AU$0.064 loss in FY 2020)The company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2021 results: Revenue: AU$11.5m (up 128% from FY 2020). Net loss: AU$15.0m (loss widened 1.9% from FY 2020).
Reported Earnings • Mar 02First half 2021 earnings released: AU$0.035 loss per share (vs AU$0.037 loss in 1H 2020)The company reported a solid first half result with improved revenues and control over costs, although losses were not reduced. First half 2021 results: Revenue: AU$5.10m (up 175% from 1H 2020). Net loss: AU$8.27m (flat on 1H 2020).
Recent Insider Transactions • Mar 26Independent Non-Executive Chairman recently bought AU$58k worth of stockOn the 23rd of March, Manik Pujara bought around 3m shares on-market at roughly AU$0.017 per share. This transaction amounted to 61% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Manik's only on-market trade for the last 12 months.
お知らせ • Feb 02Peak Processing Limited has completed a Follow-on Equity Offering in the amount of AUD 2.72 million.Peak Processing Limited has completed a Follow-on Equity Offering in the amount of AUD 2.72 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 150,000,000 Price\Range: AUD 0.017 Discount Per Security: AUD 0.00102 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 10,000,000 Price\Range: AUD 0.017 Discount Per Security: AUD 0.00102 Transaction Features: Subsequent Direct Listing
分析記事 • Jan 27Many Still Looking Away From Peak Processing Limited (ASX:PKP)Peak Processing Limited's ( ASX:PKP ) price-to-sales (or "P/S") ratio of 1.2x might make it look like a strong buy...
お知らせ • Jan 20Peak Processing Limited Announces Cessation of Employment of Brian Mbesha as CFO, Effective January 20, 2026Peak Processing Limited announced the immediate cessation of employment of its Canadian-based Chief Financial Officer (CFO), Mr. Brian Mbesha, as part of an internal restructure. This change forms part of a broader and ongoing cost optimisation program focused on strengthening financial discipline and supporting improved operational execution. Financial oversight, reporting, and controls will continue uninterrupted, led by the Company’s existing finance team, with additional interim part-time assistance from an experienced Australian-based external professional services firm accustomed to Australian reporting requirements to fulfil the CFO functions and ensure compliance and continuity during this transition period. Effective immediately on January 20, 2026.
Board Change • Jan 01High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Director Matt Adams is the most experienced director on the board, commencing their role in 2025. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Board Change • Nov 01High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Chairman of the Board Vaughan Webber is the most experienced director on the board, commencing their role in 2024. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 05Full year 2025 earnings released: AU$0.009 loss per share (vs AU$0.069 loss in FY 2024)Full year 2025 results: AU$0.009 loss per share (improved from AU$0.069 loss in FY 2024). Revenue: AU$15.5m (up 27% from FY 2024). Net loss: AU$4.84m (loss narrowed 81% from FY 2024). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.
Recent Insider Transactions • Oct 03Insider recently sold AU$201k worth of stockOn the 1st of October, Joshua Fegan sold around 11m shares on-market at roughly AU$0.019 per share. This transaction amounted to 19% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of AU$157k more than they bought in the last 12 months.
お知らせ • Oct 01Althea Group Holdings Limited, Annual General Meeting, Nov 27, 2025Althea Group Holdings Limited, Annual General Meeting, Nov 27, 2025.
お知らせ • Sep 17Althea Group Holdings Limited has completed a Follow-on Equity Offering in the amount of AUD 2.55 million.Althea Group Holdings Limited has completed a Follow-on Equity Offering in the amount of AUD 2.55 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 141,666,667 Price\Range: AUD 0.018 Discount Per Security: AUD 0.00108 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
New Risk • Aug 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$8.0m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$8.0m free cash flow). Negative equity (-AU$574k). Earnings have declined by 5.7% per year over the past 5 years. Shareholders have been substantially diluted in the past year (66% increase in shares outstanding). Minor Risk Market cap is less than US$100m (AU$18.6m market cap, or US$12.2m).
New Risk • Jul 31New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 62% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 12% per year over the past 5 years. Shareholders have been substantially diluted in the past year (62% increase in shares outstanding). Minor Risk Market cap is less than US$100m (AU$21.4m market cap, or US$13.8m).
分析記事 • Jul 29Little Excitement Around Althea Group Holdings Limited's (ASX:AGH) RevenuesAlthea Group Holdings Limited's ( ASX:AGH ) price-to-sales (or "P/S") ratio of 0.5x might make it look like a strong...
分析記事 • Apr 15Althea Group Holdings Limited's (ASX:AGH) Share Price Is Matching Sentiment Around Its RevenuesYou may think that with a price-to-sales (or "P/S") ratio of 0.3x Althea Group Holdings Limited ( ASX:AGH ) is...
New Risk • Apr 09New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 30% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 12% per year over the past 5 years. Shareholders have been substantially diluted in the past year (30% increase in shares outstanding). Market cap is less than US$10m (AU$11.0m market cap, or US$6.55m). Minor Risk Share price has been volatile over the past 3 months (15% average weekly change).
お知らせ • Feb 19Althea Group Holdings Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.Althea Group Holdings Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 119,000,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Security Name: Common Shares Security Type: Common Stock Securities Offered: 6,000,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Transaction Features: Subsequent Direct Listing
お知らせ • Feb 17Althea Group Holdings Limited Appoints Matt Adams as Non-Executive DirectorAlthea Group Holdings Limited announced the appointment of Mr. Matt Adams as a Non-Executive Director, effective 17 February 2025. Mr. Adams is an experienced finance professional with over 25 years of executive-level experience across corporate finance, restructuring, and turnaround sectors. He has held senior leadership positions, including CEO, CFO, and CRO roles for both listed and unlisted entities. He is currently the Managing Director of Dynamic Corporate Investments, a boutique corporate finance firm specialising in restructuring, corporate advisory, and investment. Mr. Adams' extensive background in financial structuring, governance, and risk management will provide valuable strategic insights to AGH as the Company continues to execute its growth initiatives.
New Risk • Feb 03New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$14.7m (US$9.05m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 14% per year over the past 5 years. Market cap is less than US$10m (AU$14.7m market cap, or US$9.05m). Minor Risk Shareholders have been diluted in the past year (27% increase in shares outstanding).
お知らせ • Jan 31Althea Group Holdings Limited Announces Penelope Dobson Intention to Retire as DirectorAlthea Group Holdings Limited announced that Penelope Dobson has advised her intention to retire as director at the annual general meeting to be held on January 31, 2025.
お知らせ • Dec 30Althea Group Holdings Limited, Annual General Meeting, Jan 31, 2025Althea Group Holdings Limited, Annual General Meeting, Jan 31, 2025.
New Risk • Dec 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 14% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (28% increase in shares outstanding). Market cap is less than US$100m (AU$17.3m market cap, or US$11.2m).
分析記事 • Dec 02Lacklustre Performance Is Driving Althea Group Holdings Limited's (ASX:AGH) 29% Price DropAlthea Group Holdings Limited ( ASX:AGH ) shares have retraced a considerable 29% in the last month, reversing a fair...
お知らせ • Oct 30Montu Group UK Ltd completed the acquisition of MyAccess Clinics business in the UK and Ireland of Althea Group Holdings Limited from Althea Group Holdings Limited (ASX:AGH).Montu Group UK Ltd agreed to acquire MyAccess Clinics business in the UK and Ireland of Althea Group Holdings Limited from Althea Group Holdings Limited (ASX:AGH) for AUD 1 million on October 17, 2024. The completion is subject to the following conditions precedent: Transfer of patient information; Execution of an IP Assignment Deed for the assignment of intellectual property rights o Provision and verification of data relating to patient numbers; Completion will occur 5 business days from the date on which the above conditions have been satisfied (or waived by Montu UK); and The Asset Sale Deed otherwise contains terms customary for a transaction of this nature, including in relation to representations and warranties and and is expected to complete in the coming weeks. Montu Group UK Ltd completed the acquisition of MyAccess Clinics business in the UK and Ireland of Althea Group Holdings Limited from Althea Group Holdings Limited (ASX:AGH) on October 29, 2024.
分析記事 • Sep 12Althea Group Holdings Limited's (ASX:AGH) Shares Bounce 39% But Its Business Still Trails The IndustryAlthea Group Holdings Limited ( ASX:AGH ) shareholders would be excited to see that the share price has had a great...
Reported Earnings • Aug 31Full year 2024 earnings released: AU$0.085 loss per share (vs AU$0.039 loss in FY 2023)Full year 2024 results: AU$0.085 loss per share (further deteriorated from AU$0.039 loss in FY 2023). Revenue: AU$30.4m (up 21% from FY 2023). Net loss: AU$32.1m (loss widened 134% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 58% per year, which means it is performing significantly worse than earnings.
お知らせ • Aug 21Althea Group Holdings Limited Announces Board Changes19 August 2024: Althea Group Holdings Limited announced that Mr. Andrew Newbold will step down from his position as Non- Executive Director and Chairman of the Board on 29 August 2024, following a scheduled board meeting. Mr. Vaughan Webber will then assume the role of Chairman, effective immediately on conclusion of this meeting. Mr. Newbold has served as Non-Executive Director and Chairman since September 2018, providing exemplary leadership and guidance during a period of significant growth and transformation for AGH. The Board extend its sincere thanks to Mr. Newbold for his dedication, strategic vision, and commitment to the Company. We wish him all the best in his future endeavours. The Board announced the appointment of Mr. Vaughan Webber as the new Non-Executive Director and Chairman of Althea Group Holdings Ltd, effective immediately upon Mr. Newbold's resignation on 29 August 2024. Mr. Webber is a seasoned company director and finance executive with over 20 years of experience, possessing an in-depth understanding of ASX-listed company operations and governance. His career highlights include: Non-Executive Director, HUB24 Ltd. (2012-2018): Joined during a board restructure to help recapitalise the business, divest non-performing divisions, and support the CEO and management team in developing a robust strategy. Independent Chairman, Wentworth Holdings Ltd. (2009-2013): Oversaw the company's restructuring, the sale of its primary business operations, and the subsequent acquisition by Thorney Opportunities Ltd.
お知らせ • Jul 17Althea Group Holdings Limited has completed a Follow-on Equity Offering in the amount of AUD 2.026662 million.Althea Group Holdings Limited has completed a Follow-on Equity Offering in the amount of AUD 2.026662 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 101,333,100 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Transaction Features: Subsequent Direct Listing
分析記事 • Jun 08Althea Group Holdings Limited's (ASX:AGH) Prospects Need A Boost To Lift SharesWith a price-to-sales (or "P/S") ratio of 0.3x Althea Group Holdings Limited ( ASX:AGH ) may be sending very bullish...
分析記事 • Feb 23Investors Continue Waiting On Sidelines For Althea Group Holdings Limited (ASX:AGH)You may think that with a price-to-sales (or "P/S") ratio of 0.6x Althea Group Holdings Limited ( ASX:AGH ) is...
お知らせ • Jan 05Althea Group Holdings Limited, Annual General Meeting, Jan 30, 2024Althea Group Holdings Limited, Annual General Meeting, Jan 30, 2024, at 17:00 AUS Eastern Standard Time. Agenda: To receive the financial statements, Directors's report and auditor's report for the Company for the financial year ended 30 June 2023; to consider the Remuneration Report; to consider the Additional 10% Placement Capacity; to consider the Re-election of Directors; to consider Short Term Incentive - Grant of Performance Rights to Joshua Fegan; to consider the Long Term Incentive - Grant of Performance Rights to Joshua Fegan; and to consider any other business that may be lawfully brought forward.
New Risk • Nov 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$7.8m free cash flow). Earnings have declined by 16% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (AU$15.4m market cap, or US$10.1m).
Reported Earnings • Sep 01Full year 2023 earnings released: AU$0.039 loss per share (vs AU$0.04 loss in FY 2022)Full year 2023 results: AU$0.039 loss per share. Revenue: AU$25.1m (up 22% from FY 2022). Net loss: AU$13.7m (loss widened 13% from FY 2022).
New Risk • Aug 29New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 19% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (AU$16.3m market cap, or US$10.5m).
お知らせ • Jul 24Althea Group Holdings Limited Announces Approval for Althea CBD12:THC10 for Reimbursement in IrelandAlthea Group Holdings Limited announced that Ireland's Primary Care Reimbursement Service (`PCRS') has approved Althea CBD12:THC10 for reimbursement in Ireland. In a follow up to the Company's ASX announcement on 20 May 2022, Althea CBD12:THC10 has now been added to the PCRS in the Republic of Ireland, making it free of charge for Irish patients. The Rapid Review Submission for Althea CBD12:THC10 cannabis oil (50 ml), as included in Schedule 1 of the Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) (Amendment) Regulations 2023, has resulted in the assignment of administrative codes to facilitate access to the product in line with the Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) Regulations 2019 (as amended) for the specified therapeutic indications below, with an effective date of 1st August 2023: Spasticity associated with multiple sclerosis resistant to all standard therapies and interventions; Intractable nausea and vomiting associated with chemotherapy, despite the use of standard anti-emetic regimes. The agreed reimbursement price for Althea CBD12:THC10 (50ml) is 327.89, or approximately AUD 540. Multiple sclerosis (MS) is a complex inflammatory disease of the central nervous system (CNS). The onset of the disease is typically between 20 to 40 years of age, and up to 9,000 people live with this chronic condition in Ireland. Approximately 70% to 80% of adults with cancer experience chemotherapy-induced nausea and vomiting (CINV). CINV remains one of the most distressing symptoms associated with cancer therapy and is associated with decreased adherence to chemotherapy.
分析記事 • Apr 18Althea Group Holdings Limited (ASX:AGH) Shares Fly 28% But Investors Aren't Buying For GrowthAlthea Group Holdings Limited ( ASX:AGH ) shareholders are no doubt pleased to see that the share price has bounced 28...
お知らせ • Feb 03Althea Group Holdings Limited announced that it has received AUD 2.2 million in funding from Obsidian Global Partners, LLCAlthea Group Holdings Limited announced that it has issued unsecured convertible notes for gross proceeds of AUD 2,200,000 on February 3, 2023. The transaction included participation from institutional investor Obsidian Global Partners, LLC. The notes are convertible at a conversion price of $1.5 (AUD 2.1153) into 54,206,846 common shares of the company. The company will pay no interest on the notes. The investor may in its discretion elect to convert one or more convertible securities at the relevant conversion price by providing the company notice, provided that, where an issue of shares would result in the voting power in the company of the investor or any other person exceeding 19.99%.The notes will mature twelve months from the date which is five business days from the date of execution of the relevant agreement. The company also issued 4,800,000 options with an an exercise price equal to 200% of the 5 actual trading days immediately prior to mutual execution of the relevant agreement. The company will pay fee of 6% of the purchase price and AUD 15,000 upfront as legal cost of the transaction.
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Non-Executive Director Jakob Ripshtein was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Nov 07Althea Group Holdings Limited, Annual General Meeting, Nov 29, 2022Althea Group Holdings Limited, Annual General Meeting, Nov 29, 2022, at 17:00 AUS Eastern Standard Time. Agenda: To receive the financial statements, Directors' report and auditor's report for the Company for the financial year ended 30 June 2022; to consider approval for Additional 10% Placement Capacity; to consider re-election of Directors; and to consider other matters.
お知らせ • Sep 15Althea Group Holdings Limited Launches Next Generation ProductsAlthea Group Holdings Limited announce its medical cannabis business Althea, has launched two innovative new products to meet patient needs. Commencing with Althea CBD25, Althea has released an exclusive range of soft gelatine capsules (`soft gel capsules') containing Althea's trusted full-spectrum cannabis extract, manufactured to EU-GMP standard. Each capsule of Althea CBD25 contains 25mg of cannabidiol (CBD), and less than 0.25mg of delta-9- tetrahydrocannabinol (THC) per capsule. As a full-spectrum product, Althea CBD25 also contains terpenes, flavonoids and other phytochemicals. Phytochemicals including cannabinoids and terpenes may have synergistic effects, a hypothesis often referred to as the `entourage effect'. Althea's unique range of soft gel capsules are administered orally, offering a gradual onset and extended duration of effect, compared to the rapid onset and shorter duration of effect for products requiring inhalation (dried flower products). In vitro studies have demonstrated effective disintegration of Althea soft gel capsules in less than 10 minutes and there is no significant difference in pharmacokinetic properties expected for patients converting to soft gel capsules from Althea's first generation (or other suppliers') bottled oil products. Why launch Althea CBD25 soft gel capsules?: Solid oral dosage formats are the gold-standard pharmaceutical preparation globally and are widely recognised for maximising patient acceptability and compliance. A consumer preference survey of soft gel capsules versus conventional solid oral dosage forms identified soft gel capsules as the first choice of delivery format. First generation bottled cannabis oils remain a challenge for patients with visual or dexterity impairments, taste intolerances and for patients residing in aged care facilities and hospitals (where medicines are allocated and dispensed). Althea soft gel capsules provide familiarity, convenience and confidence for doctors and patients, delivering precise and standardised dosing of the medicine. The release of soft gel capsules will continue to position Althea as a leader and innovator in the global medical cannabis industry. Schedule 3 Pharmacist only medicine (Australia): Subject to required regulatory approvals, Althea CBD25 soft gel capsules are a candidate to be supplied under the Therapeutic Goods Administration's (TGA) Schedule 3 (Pharmacist Only Medicine) entry for eligible CBD products. This new, non-prescription cannabis channel could allow Australian patients to purchase Althea CBD25 over the counter upon consultation with a pharmacist, without the need for a prescription. What is Althea THC25 dried flower?: Althea THC25 is a new and exclusive ultra-high THC cannabis dried flower product, containing 25% THC and less than 1% of CBD. Greenhouse grown in Canada and produced to meet the stringent standards of a pharmaceutical preparation for inhalation, Althea THC25 also retains a rich terpene and flavonoid profile. Althea THC25 is Althea's highest-concentrated THC dried flower product and will be available across all its `core' international medical cannabis markets (including Germany, UK and Australia). Why launch Althea THC25 dried flower?: Althea has until now focussed primarily on cannabis extracts, however, with a growing number of consumers accessing cannabis dried flower products via the medical framework, Althea THC25 has been introduced to capitalize on this sizeable market opportunity. Market data indicates that dried flower cannabis is the fastest growing product category in Australia and now accounts for 50.6% of the total market (+450% annual growth). The dried flower market is primarily driven by highly concentrated THC products, representing just over half of the total dried flower category. Althea THC25, the first of three new planned dried flower offerings, will be launched globally and supported by Althea's infield sales team, which will focus on educating the 1,400+ registered prescribers in the Althea network.
Reported Earnings • Sep 01Full year 2022 earnings released: AU$0.04 loss per share (vs AU$0.061 loss in FY 2021)Full year 2022 results: AU$0.04 loss per share (up from AU$0.061 loss in FY 2021). Revenue: AU$20.5m (up 78% from FY 2021). Net loss: AU$12.1m (loss narrowed 19% from FY 2021). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings.
分析記事 • Jul 11We Think Althea Group Holdings (ASX:AGH) Needs To Drive Business Growth CarefullyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
お知らせ • May 20Health Products Regulatory Authority Approves Althea CBD12:THC10 Product of Althea Group Holdings LimitedAlthea Group Holdings Limited announced that the Health Products Regulatory Authority has approved Althea CBD12:THC10 product for prescription and supply in the Republic Ireland. Details: Althea is to enter the Irish medicinal cannabis market following the approval of Althea CBD12:THC10 by Ireland's medicines regulator, HPRA and the Minister for Health. Althea CBD12:THC10 is one of a limited number of medicinal cannabis products available for prescription and supply in the Republic of Ireland. The Company is seeking further product approvals in Ireland. An application will follow for Althea CBD12:THC10 to be added to the Primary Care Reimbursement Service in the Republic of Ireland as part of the Medicinal Cannabis Access Programme (MCAP), making it free of charge for Irish patients prescribed the treatment under the Medicinal Cannabis Access Programme.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Non-Executive Director Jakob Ripshtein was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
分析記事 • Feb 28The Consensus EPS Estimates For Althea Group Holdings Limited (ASX:AGH) Just Fell A LotThe latest analyst coverage could presage a bad day for Althea Group Holdings Limited ( ASX:AGH ), with the covering...
分析記事 • Feb 25Is Althea Group Holdings (ASX:AGH) In A Good Position To Invest In Growth?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Board Change • Feb 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Non-Executive Director Jakob Ripshtein was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Breakeven Date Change • Nov 24No longer forecast to breakevenThe analyst covering Althea Group Holdings no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of AU$5.00m in 2023. New forecast suggests the company will make a loss of AU$100.0k in 2023.
Reported Earnings • Sep 01Full year 2021 earnings released: AU$0.06 loss per share (vs AU$0.064 loss in FY 2020)The company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2021 results: Revenue: AU$11.5m (up 128% from FY 2020). Net loss: AU$15.0m (loss widened 1.9% from FY 2020).
お知らせ • Aug 25Althea Group Holdings Limited announced that it expects to receive AUD 10.644452 million in fundingAlthea Group Holdings Limited announced a private placement of 44,351,885 common shares at an issue price of AUD 0.24 per share for gross proceeds of AUD 10,644,452.40 on August 25, 2021. The transaction will include participation from from existing institutional shareholders, new institutional investors and new sophisticated investors. The transaction is expected to close on August 31, 2021.
Price Target Changed • May 06Price target decreased to AU$1.13Down from AU$1.48, the current price target is provided by 1 analyst. New target price is 169% above last closing price of AU$0.42. Stock is up 6.3% over the past year.
分析記事 • Mar 13When Will Althea Group Holdings Limited (ASX:AGH) Become Profitable?We feel now is a pretty good time to analyse Althea Group Holdings Limited's ( ASX:AGH ) business as it appears the...
Reported Earnings • Mar 02First half 2021 earnings released: AU$0.035 loss per share (vs AU$0.037 loss in 1H 2020)The company reported a solid first half result with improved revenues and control over costs, although losses were not reduced. First half 2021 results: Revenue: AU$5.10m (up 175% from 1H 2020). Net loss: AU$8.27m (flat on 1H 2020).
お知らせ • Feb 11Althea Group Holdings Limited Completes the Export of Its First Commercial Shipment of Althea Products to UK-Based Medicinal Cannabis Distributor Grow Pharma GroupAlthea Group Holdings Limited announced that it has completed the export of its first commercial shipment of Althea products to UK-based medicinal cannabis distributor Grow Pharma Group (`Grow Pharma'). A medicinal cannabis supply agreement was signed by the two parties last year, allowing Grow Pharma to distribute Althea products in the UK, in parallel to the Company's own existing sales channel. Following initial success with products supplied to Grow Pharma from its UK inventory, Althea recently expanded its agreement with Grow Pharma to include two further jurisdictions, including the Isle of Man and Guernsey. The Isle of Man and Guernsey are self-governing dependencies of the Crown and medicinal cannabis has been legal in both territories since 2018 and 2019, respectively.
お知らせ • Feb 10Althea Group Holdings Limited Completes First Shipment of Products to GermanyAlthea Group Holdings Limited announced that it has completed its first shipment of Althea medicinal cannabis oil products to the Company's local partner in Germany, Nimbus Health GmbH (`Nimbus'). The initial shipment of Althea medicinal cannabis oil products valued at approximately $1,000,000 (EUR 640,000) has arrived at the Nimbus facility and will be distributed through a large network of existing partnering pharmacies. In conjunction with Nimbus, Althea will generate its own sales via new and existing customers and will not rely on third party wholesalers for repeat purchase orders. Exclusive supply & distribution agreement: Althea announced a Memorandum of Understanding in November 2019, followed by a Supply and Distribution Agreement in May 2020. Under the agreement, Althea will receive payment for products supplied to Nimbus, along with 50% of net profit. In addition, Althea will retain ownership of all real-world anonymized patient data collected through its industry-leading medical app, Althea ConciergeTM. To launch the Althea brand in Germany, Nimbus is adopting the same successful market access strategy implemented by the Company in Australia and the UK.
分析記事 • Feb 06Can You Imagine How Althea Group Holdings' (ASX:AGH) Shareholders Feel About The 28% Share Price Increase?These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But investors can...
お知らせ • Dec 18Althea Group Holdings Limited Announces Availability of CBD Medicines For Over-The-Counter Sale from 2021Althea Group Holdings Limited announced that a major regulatory change has been confirmed in relation to the status of cannabidiol (CBD) in Australia. TGA confirms new Schedule 3 entry for CBD The Therapeutic Goods Administration issued its final decision on proposed amendments to the Poison Standard which, amongst other amendments, sees a new Schedule 3 entry created for cannabidiol. The date of effect of the decision is 1 February 2021, bringing it forward from the date of 1 June 2021 as proposed in the interim decision. The amendment will allow CBD to be supplied for therapeutic use under a new Schedule 3 (Pharmacist Only Medicine) entry. This new, non-prescription cannabis channel would allow Australian patients to purchase CBD products over the counter upon consultation with a pharmacist, without the need for a prescription. Maximum recommended daily dose increased The final decision included a modification to the dose specified in the interim decision, increasing from 60 mg/day, up to 150 mg/day. The decision paves the way for Althea's top selling full-spectrum CBD product, Althea CBD100, to be made available under Schedule 3 (currently sold in Schedule 4 - Prescription Only Medicine). Althea CBD100, along with several other CBD preparations currently in development, would need to be included in the Australian Register of Therapeutic Goods (ARTG) to be made available for sale as Schedule 3 products. The Company maintains robust drug master files for its medications and is confident in its ability to meet the ARTG requirements for Schedule 3 preparations.
お知らせ • Dec 16Althea Group Holdings Limited announced that it expects to receive AUD 6 million in fundingAlthea Group Holdings Limited (ASX:AGH) announced a private placement of 13,636,364 common shares at an issue price of AUD 0.44 per share for gross proceeds of AUD 6,000,000 on December 14, 2020. The transaction is expected to close December 21, 2020. The transaction will include participation from to institutional, sophisticated and professional investors.
分析記事 • Dec 04What You Need To Know About Althea Group Holdings Limited's (ASX:AGH) Investor CompositionEvery investor in Althea Group Holdings Limited ( ASX:AGH ) should be aware of the most powerful shareholder groups...
お知らせ • Jun 22Althea Group Holdings Limited(ASX:AGH) dropped from S&P/ASX Emerging Companies IndexAlthea Group Holdings Limited(ASX:AGH) dropped from S&P/ASX Emerging Companies Index